——The funding will propel the clinical development of core assets, including the IRAK4 degrader LT-002-158, and expand the company’s proprietary TPD platform.SHANGHAI, China, [December 18], 2025 – Lea

SHANGHAI & SHAOXING, China – July 9, 2025 – Leadingtac Pharmaceutical Co., Ltd., a clinical-stage biotech company focused on innovative drug discovery for autoimmune diseases and oncology, announced today it has dosed the first patient in its Phase Ic clinical trial of LT-002 for the treatment of moderate-to-severe hidradenitis suppurativa (HS).

June 5, 2025 – Leadingtac Pharmaceutical Co., Ltd. ("Leadingtac"), a clinical stage biotech company focused on innovative drug discovery and development in autoimmune disease and oncology, announced today that the first patient has been dosed in the Phase Ic clinical study of its independently developed IRAK4 protein degrader LT-002 for the treatment of atopic dermatitis (AD)

Leadingtac announced on March 18, 2025 that the Phase I human clinical trial of LT-002 (IRAK4 protein degrader), a small molecule drug candidate for the treatment of hidradenitis suppurativa, atopic dermatitis and other dermatological disorders, has been successfully completed in all healthy volunteers. volunteers and the last subject will be discharged on March 31st. ​

On February 9, Shaoxing Keqiao Economic and Technological Development Zone Leaders Conference was held in Jin Keqiao Science and Technology City. Keqiao Management Committee honored various entities and individuals with outstanding performance in various fields in the year of 2024.

Shanghai Leadingtac Pharmaceutical Co., Ltd. (hereinafter referred to as: Leadingtac) , a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, recently announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million).

Shanghai Leadingtac Pharmaceutical Co., Ltd. (hereinafter referred to as "Leadingtac"), a clinical-stage biopharmaceutical company focused on the development of protein degrader for the treatment of chronic inflammatory and autoimmune diseases, announced on June 25th that the first healthy volunteer has been dosed in Phase 1 trial evaluating the safety, pharmacokinetic profile and food effects of LT-002.

Recently, Dr. Yan Feng, the founder of LeadingTac, was selected as one of the "Pearl Leading Talent" in Pudong New Area in 2023 after passing the strict evaluation by the Talent Expert Group of Pudong New Area Committee for his targeted protein degradation project.

On December 6, 2023 Pudong International Talent Port Forum, with the theme of "Leadership, Gathering Momentum and Leap", was held at the Zhangjiang Science Hall. The first batch of "Pearl Program" tal

Following the U.S. FDA approval of LT-002 for the treatment of Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) on May 24, 2023 (NCT06082323), Leadingtac received the clearance from the CDE of